Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

MNPR

+ Watchlist+ Portfolio

Monopar Therapeutics Inc.

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$71.06
52-Week Range
$50.07 – $124.82
Market Cap
$479.46M
P/E (TTM)
—
EPS (TTM)
-2.44
Dividend Yield
0.00%
Advanced Metrics
Price/Book
3.77
PEG Ratio
—
Return on Equity
-15.34%
Return on Assets
-11.61%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
43.55
Debt/Equity
0.00
Total Debt
$357.26K
Free Cash Flow
$-9.40M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$350.37M

Market Snapshot

About

Monopar Therapeutics is a clinical-stage biopharmaceutical company developing proprietary therapeutics for cancer patients. The company focuses on camsirubicin for advanced soft tissue sarcoma and MNPR-101 for advanced cancers.